Analysts Expect ResMed Inc. (NYSE:RMD) to Post $0.84 EPS

Equities research analysts expect that ResMed Inc. (NYSE:RMD) will post earnings of $0.84 per share for the current quarter, according to Zacks. Three analysts have issued estimates for ResMed’s earnings. The highest EPS estimate is $0.88 and the lowest is $0.76. ResMed posted earnings of $0.81 per share during the same quarter last year, which would indicate a positive year over year growth rate of 3.7%. The firm is scheduled to report its next earnings results on Thursday, October 24th.

On average, analysts expect that ResMed will report full-year earnings of $3.92 per share for the current fiscal year, with EPS estimates ranging from $3.64 to $4.22. For the next year, analysts expect that the company will report earnings of $4.28 per share, with EPS estimates ranging from $3.98 to $4.49. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow ResMed.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, July 25th. The medical equipment provider reported $0.95 EPS for the quarter, topping the consensus estimate of $0.92 by $0.03. The company had revenue of $705.00 million for the quarter, compared to analysts’ expectations of $701.56 million. ResMed had a return on equity of 26.49% and a net margin of 15.52%. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.95 earnings per share.



Several research analysts have recently commented on the company. JPMorgan Chase & Co. upgraded ResMed from an “underweight” rating to a “neutral” rating and set a $95.00 target price for the company in a research note on Thursday, April 18th. Goldman Sachs Group upgraded ResMed from a “neutral” rating to a “buy” rating in a research note on Monday, July 29th. Zacks Investment Research upgraded ResMed from a “hold” rating to a “buy” rating and set a $131.00 target price for the company in a research note on Monday, July 8th. ValuEngine upgraded ResMed from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, UBS Group upgraded ResMed from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $122.00 to $140.00 in a research note on Monday, July 29th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. ResMed presently has an average rating of “Buy” and a consensus price target of $121.50.

ResMed stock traded up $1.18 during midday trading on Thursday, reaching $132.33. The stock had a trading volume of 314,648 shares, compared to its average volume of 819,539. The stock has a market capitalization of $18.91 billion, a PE ratio of 36.35, a P/E/G ratio of 3.17 and a beta of 0.47. ResMed has a 1-year low of $90.64 and a 1-year high of $135.45. The company’s fifty day moving average is $126.12. The company has a quick ratio of 1.43, a current ratio of 2.06 and a debt-to-equity ratio of 0.61.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 19th. Investors of record on Thursday, August 15th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Wednesday, August 14th. This is an increase from ResMed’s previous quarterly dividend of $0.37. This represents a $1.56 annualized dividend and a yield of 1.18%. ResMed’s payout ratio is 40.66%.

In related news, Director John P. Wareham sold 44,342 shares of the business’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $113.86, for a total value of $5,048,780.12. Following the completion of the sale, the director now directly owns 24,085 shares in the company, valued at approximately $2,742,318.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert Andrew Douglas sold 4,154 shares of the business’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $118.44, for a total value of $491,999.76. Following the completion of the sale, the insider now owns 48,721 shares of the company’s stock, valued at $5,770,515.24. The disclosure for this sale can be found here. Insiders sold a total of 110,167 shares of company stock valued at $13,203,891 over the last 90 days. 1.24% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Westside Investment Management Inc. acquired a new position in ResMed in the 2nd quarter valued at $26,000. Farmers & Merchants Investments Inc. raised its holdings in ResMed by 49.0% in the 1st quarter. Farmers & Merchants Investments Inc. now owns 295 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 97 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new position in ResMed in the 2nd quarter valued at $40,000. CSat Investment Advisory L.P. raised its holdings in ResMed by 97.0% in the 2nd quarter. CSat Investment Advisory L.P. now owns 388 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 191 shares in the last quarter. Finally, Ossiam acquired a new position in ResMed in the 2nd quarter valued at $54,000. Institutional investors and hedge funds own 66.54% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Recommended Story: What is an investor looking for in an SEC filing?

Get a free copy of the Zacks research report on ResMed (RMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.